Induction Cisplatin and Capecitabine Followed by Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma

• Status: Completed
• Trial end date: 2017-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To prospectively evaluate the short-term efficacy and toxicity of induction chemotherapy with cisplatin and capecitabine followed by concurrent chemoradiotherapy (CCRT) in the treatment of locally advanced nasopharyngeal carcinoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University of Hong Kong-Shenzhen Hospital
• Treatments: Capecitabine; Cisplatin

Criteria

Inclusion Criteria:

• Pathological confirmed nasopharyngeal carcinoma.

• Staged as III to IVB.

• 18-75 years old.

• Performance status ≤2.

• No previous chemotherapy or radiotherapy.

• No concurrent malignancies or a history of other malignancies.

• Adequate bone marrow function (absolute neutrophil count ≥1.5×109/L, platelets ≥100×109/L).

• Adequate liver and renal function (serum bilirubin and serum transaminase levels less than twice the upper limit of normal, creatinine clearance ≥ 60ml/min).

• Without serious co-morbidity.

Exclusion Criteria:

• Stage I-II or IVC.

• Allergic to cisplatin or capecitabine

• Age <18 or >75

• Performance Status >2.

• Without adequate bone marrow or liver function or renal function.

• Severe co-morbidity and can not tolerate chemotherapy.

• Other conditions not suitable for the study on the discretion of charging doctor.